相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
N. Colombo et al.
BRITISH JOURNAL OF CANCER (2013)
Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials
Aung Naing
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The Precise Chemical-Physical Nature of the Pharmacore in FK506 Binding Protein Inhibition: ElteX, a New Class of Nanomolar FKBP12 Ligands
Maria Raffaella Martina et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Increasing the Efficiency of Ligands for FK506-Binding Protein 51 by Conformational Control
Yansong Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Large FK506-Binding Proteins Shape the Pharmacology of Rapamycin
Andreas M. Maerz et al.
MOLECULAR AND CELLULAR BIOLOGY (2013)
Effects of tacrolimus on action potential configuration and transmembrane ion currents in canine ventricular cells
Laszlo Szabo et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2013)
Regulation of Immune Responses by mTOR
Jonathan D. Powell et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
The neuroregenerative mechanism mediated by the Hsp90-binding immunophilin FKBP52 resembles the early steps of neuronal differentiation
H. R. Quinta et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Temsirolimus: a safety and efficacy review
Ronald M. Bukowski
EXPERT OPINION ON DRUG SAFETY (2012)
mTOR, metabolism, and the regulation of T-cell differentiation and function
Adam T. Waickman et al.
IMMUNOLOGICAL REVIEWS (2012)
Evaluation of Synthetic FK506 Analogues as Ligands for the FK506-Binding Proteins 51 and 52
Ranganath Gopalakrishnan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Prolyl Isomerase Pin1 Regulates Neuronal Differentiation via β-Catenin
Kazuhiro Nakamura et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
Suppression of EGFR Autophosphorylation by FKBP12
Sebastian Mathea et al.
BIOCHEMISTRY (2011)
Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors
Beverly L. Falcon et al.
CANCER RESEARCH (2011)
Immunophilins and Cardiovascular Complications
E. Calderon-Sanchez et al.
CURRENT MEDICINAL CHEMISTRY (2011)
The Chemical Biology of Immunophilin Ligands
S. Gaali et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Targeting FKBP isoforms with small-molecule ligands
Elizabeth A. Blackburn et al.
CURRENT OPINION IN PHARMACOLOGY (2011)
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
Seth A. Wander et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Victor M. Rivera et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma
Brian L. Teng et al.
MOLECULAR ONCOLOGY (2011)
Mechanisms of mTOR inhibitor resistance in cancer therapy
Jennifer S. Carew et al.
TARGETED ONCOLOGY (2011)
Creating Diverse Target-Binding Surfaces on FKBP12: Synthesis and Evaluation of a Rapamycin Analogue Library
Xianghong Wu et al.
ACS COMBINATORIAL SCIENCE (2011)
The role of mTOR in memory CD8+T-cell differentiation
Koichi Araki et al.
IMMUNOLOGICAL REVIEWS (2010)
Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis
Pallavi V. Pople et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2010)
Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management
Shireena Desai et al.
LIVER INTERNATIONAL (2010)
IMPROVEMENT OF CARDIOVASCULAR RISK FACTORS AND COSMETIC SIDE EFFECTS IN KIDNEY TRANSPLANT RECIPIENTS AFTER CONVERSION TO TACROLIMUS
Josef Zadrazil et al.
BIOMEDICAL PAPERS-OLOMOUC (2009)
Rapamycin induces transactivation of the EGFR and increases cell survival
D. Chaturvedi et al.
ONCOGENE (2009)
mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
Juan M. Garcia-Martinez et al.
BIOCHEMICAL JOURNAL (2008)
mTOR inhibitors in the treatment of cancer
Angelica Fasolo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation
Feng Hong et al.
MOLECULAR CELL (2008)
FKBP Family Proteins: Immunophilins with Versatile Biological Functions
Cong Bao Kang et al.
NEUROSIGNALS (2008)
Structure-based classification of 45 FK506-binding proteins
J. A. Somarelli et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2008)
Targeting mammalian target of rapamycin (mTOR) for health and diseases
Chi Kwan Tsang et al.
DRUG DISCOVERY TODAY (2007)
Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins
Matthias Weiwad et al.
BIOCHEMISTRY (2006)
The specific FKBP38 inhibitor N-(N′,N′-dimethylcarboxamidomethyl) cycloheximide has potent neuroprotective and neurotrophic properties in brain ischemia
Frank Edlich et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Drug therapy - Coronary-artery stents
PW Serruys et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis
W Hoetzenecker et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2005)
FKBP immunophilin patents for neurological disorders
RE Babine et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2005)
Non-FK506-binding protein-12 neuroimmunophilin Ligands increase neurite elongation and accelerate nerve regeneration
BG Gold et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2005)
Functions and regulation of transforming growth factor-beta (TGF-β) in the prostate
D Danielpour
EUROPEAN JOURNAL OF CANCER (2005)
Conversion from cyclosporine to tacrolimus after renal transplantation improves cardiovascular risk factors
H Hohage et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2005)
Tacrolimus ointment: the treatment of atopic dermatitis and other inflammatory cutaneous disease
CL Carroll et al.
EXPERT OPINION ON PHARMACOTHERAPY (2004)
Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload
JR McMullen et al.
CIRCULATION (2004)
Synthesis and evaluation of chiral bicyclic proline FKBP12 ligands
DC Limburg et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery
JW Moses et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Pimecrolimus: A review
AK Gupta et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2003)
Mechanisms of TGF-β signaling from cell membrane to the nucleus
YG Shi et al.
CELL (2003)
The immunophilin-ligands FK506 and V-10,367 mediate neuroprotection by the heat shock response
A Klettner et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis
N Wakata et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2003)
Use of parallel-synthesis combinatorial libraries for rapid identification of potent FKBP12 inhibitors
C Choi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002)
A new substrate specificity for acyl transferase domains of the ascomycin polyketide synthase in Streptomyces hygroscopicus
CD Reeves et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The neuroprotective actions of FK506 binding protein ligands:: neuronal survival is triggered by de novo RNA synthesis, but is independent of inhibition of JNK and calcineurin
A Klettner et al.
MOLECULAR BRAIN RESEARCH (2001)
Pimecrolimus (Elidel, SDZ ASM 981) - Preclinical pharmacologic profile and skin selectivity
A Stuetz et al.
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2001)
Failure of GPI compounds to display neurotrophic activity in vitro and in vivo
A Bocquet et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2001)
FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle
B Aghdasi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
FK506, an immunosuppressant targeting calcineurin function
FJ Dumont
CURRENT MEDICINAL CHEMISTRY (2000)
Applications of tacrolimus for the treatment of skin disorders
T Assmann et al.
IMMUNOPHARMACOLOGY (2000)
分享论文
